• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172340 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  & v2 w& ?9 E. J+ b" c: k

  O# }4 }2 `, C. l! [2 ]8 _- O
1 A3 _5 ~" Q% D5 t2 C/ O2 uSub-category:
, Q) C  k8 N  [# Q" m' e% R; aMolecular Targets
; a1 \! T* w, l( y0 ~# @/ C" ~" |$ S0 V; y$ L. i
8 E) w9 l! p* V. n+ c' b: b
Category:+ F& q( O% ^/ ]! \1 f9 w6 L4 K
Tumor Biology 2 E8 v4 d9 X" j8 e$ A( l/ o( S

$ n3 C6 M& r5 K8 z6 E! l& C6 y5 j0 [2 C  ^
Meeting:/ B2 |/ M* q" _0 I* ?) |( r: b9 D
2011 ASCO Annual Meeting
7 K* S% p' _( ?7 x( I* l- d) c8 A4 `
6 n7 x' C, ^9 f  a& V. @
5 L8 A9 G! H/ F: o6 g$ j8 ~0 kSession Type and Session Title:4 v9 Y- F- M5 I- a' G
Poster Discussion Session, Tumor Biology 2 _" D: S  b  D# ~- Q
/ d$ H; g$ x" W" u
5 b9 t2 B/ E& C3 S2 l: @9 d2 h9 l0 D% x
Abstract No:9 |6 W( E9 n  ^$ |" F
10517
0 z* o+ ^3 V$ ?5 B7 q4 ~; O9 v' X8 E" s- ~
9 R0 r2 v# L9 a/ t* H+ K- V5 ~
Citation:
! r9 r9 a0 ^% o8 tJ Clin Oncol 29: 2011 (suppl; abstr 10517)
/ H6 y; v8 J: T7 f3 @9 n: W# A  }2 H
1 t5 t6 ~; q& f! |4 T$ `3 U9 G, W: E# F: X
Author(s):6 S& b* |4 J8 P- m/ f$ L
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
3 ^# R9 c6 o5 o- B' W" z: A! n. |( N
7 K+ T3 J' a# ^) E4 Z( c
3 S5 z- @  h9 C
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
8 u1 i) D: ~# U* z1 m
4 G: B: i0 z4 v! {8 s  t; z' FAbstract Disclosures. s9 b6 D4 _1 X* O7 d% S1 u! V
+ [# t# O% w1 w. J' H
Abstract:% }, ?( y( v* l3 b( y' v. O3 R

3 p1 D) a1 o: j: ?5 k  L: r; n4 C6 d, c) K7 K/ {) |" p' u
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# J+ v6 @3 `( B# f

" ?( o, _' y: U: A
. y& G# @  G" R2 o
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
: ]) k' a* W# W" G没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

. a1 ^% e9 g  Q& s化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 0 @0 b) L- f" l" [: o- }
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。- r+ ~* w! c' }( H* U4 d
ALK一个指标医院要900多 ...
( J1 l& n$ G6 N$ U
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?$ b( T3 g& X9 U; e1 a* `7 r* D

4 Y6 I6 m! o1 ?. K6 l1 V: O现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表